Xilio Therapeutics Posts $9.98 Million in Q3 2026 Revenue

Xilio Therapeutics generated $9.98 million in collaboration and license revenue in the third quarter of 2026, while recording a net loss of $0.30 per share on both basic and diluted bases. The quarter ended Sept. 30. Revenue totaled $9.984 million, rounded to $10.0 million, compared with $19.1 million in the third quarter of 2025. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.